Cathepsin B deficiency ameliorates liver lipid deposition, inflammatory cell infiltration, and fibrosis after diet-induced nonalcoholic steatohepatitis.

[1]  A. Gastaldelli,et al.  Crosstalk between adipose tissue insulin resistance and liver macrophages in Non Alcoholic Fatty Liver Disease. , 2019, Journal of hepatology.

[2]  P. Libby,et al.  Differential Roles of Cysteinyl Cathepsins in TGF-β Signaling and Tissue Fibrosis , 2019, iScience.

[3]  T. Murohara,et al.  Cathepsin S Deficiency Mitigated Chronic Stress–Related Neointimal Hyperplasia in Mice , 2019, Journal of the American Heart Association.

[4]  P. Libby,et al.  Cysteine protease cathepsins in cardiovascular disease: from basic research to clinical trials , 2018, Nature Reviews Cardiology.

[5]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[6]  Huimin Wu,et al.  Effect of modulation of PPAR-γ activity on Kupffer cells M1/M2 polarization in the development of non-alcoholic fatty liver disease , 2017, Scientific Reports.

[7]  R. Schwabe,et al.  Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis. , 2016, Cell metabolism.

[8]  D. Erion,et al.  Hepatocyte-Specific Disruption of CD36 Attenuates Fatty Liver and Improves Insulin Sensitivity in HFD-Fed Mice. , 2016, Endocrinology.

[9]  Marko Novinec,et al.  Human cathepsin L, a papain‐like collagenase without proline specificity , 2015, The FEBS journal.

[10]  M. Tomizawa,et al.  Triglyceride is strongly associated with nonalcoholic fatty liver disease among markers of hyperlipidemia and diabetes. , 2014, Biomedical reports.

[11]  S. Marchand-Adam,et al.  Regulation of TGF-β1-driven Differentiation of Human Lung Fibroblasts , 2014, The Journal of Biological Chemistry.

[12]  S. Hazen,et al.  OxNASH Score Correlates with Histologic Features and Severity of Nonalcoholic Fatty Liver Disease , 2011, Digestive Diseases and Sciences.

[13]  I. Bergheim,et al.  In Vitro and in Vivo Models of Non-Alcoholic Fatty Liver Disease (NAFLD) , 2013, International journal of molecular sciences.

[14]  F. Eren,et al.  Linking Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: From Bedside to Bench and Back , 2013 .

[15]  Zheng Zhang,et al.  Liver fibrosis: mechanisms of immune-mediated liver injury , 2011, Cellular and Molecular Immunology.

[16]  Guido Gerken,et al.  The interaction of hepatic lipid and glucose metabolism in liver diseases. , 2012, Journal of hepatology.

[17]  A. Moles,et al.  Cathepsin B Overexpression Due to Acid Sphingomyelinase Ablation Promotes Liver Fibrosis in Niemann-Pick Disease* , 2011, The Journal of Biological Chemistry.

[18]  S. Bischoff,et al.  Role of tumor necrosis factor α (TNFα) in the onset of fructose-induced nonalcoholic fatty liver disease in mice. , 2011, The Journal of nutritional biochemistry.

[19]  I. Leclercq,et al.  Animal models for the study of hepatic fibrosis. , 2011, Best practice & research. Clinical gastroenterology.

[20]  J. González‐Gallego,et al.  Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C , 2011, Gut.

[21]  K. Moore,et al.  Role of scavenger receptor A and CD36 in diet-induced nonalcoholic steatohepatitis in hyperlipidemic mice. , 2010, Gastroenterology.

[22]  J. Tschopp,et al.  NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? , 2010, Nature Reviews Immunology.

[23]  S. Bischoff,et al.  Toll‐like receptor 4 is involved in the development of fructose‐induced hepatic steatosis in mice , 2009, Hepatology.

[24]  S. Erickson.  Nonalcoholic fatty liver disease The author's work is supported by a Merit Award from the Department of Veterans Affairs and by DK-072187 from the National Institutes of Health. Published, JLR Papers in Press, December 12, 2008. , 2009, Journal of Lipid Research.

[25]  A. Moles,et al.  Cathepsins B and D drive hepatic stellate cell proliferation and promote their fibrogenic potential , 2009, Hepatology.

[26]  X. Su,et al.  Cellular fatty acid uptake: a pathway under construction , 2009, Trends in Endocrinology & Metabolism.

[27]  Z. Younossi,et al.  Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. , 2008, Cleveland Clinic journal of medicine.

[28]  C. McClain,et al.  Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. , 2008, Journal of hepatology.

[29]  Natalie J Torok,et al.  Nonalcoholic steatohepatitis and the metabolic syndrome. , 2008, Metabolic syndrome and related disorders.

[30]  J. Delgado.  Evolving trends in nonalcoholic fatty liver disease. , 2008, European journal of internal medicine.

[31]  R. Rector,et al.  Non-alcoholic fatty liver disease and the metabolic syndrome: an update. , 2008, World journal of gastroenterology.

[32]  P. Portincasa,et al.  Non-alcoholic fatty liver disease in the metabolic syndrome. , 2007, Current pharmaceutical design.

[33]  Giulio Gabbiani,et al.  The myofibroblast: one function, multiple origins. , 2007, The American journal of pathology.

[34]  Christoph Peters,et al.  Cathepsin L Deficiency Reduces Diet-Induced Atherosclerosis in Low-Density Lipoprotein Receptor-Knockout Mice , 2007, Circulation.

[35]  N. Abumrad,et al.  Role of CD36 in membrane transport and utilization of long-chain fatty acids by different tissues , 2001, Journal of Molecular Neuroscience.

[36]  E. J. Lee,et al.  PPARgamma activation induces CD36 expression and stimulates foam cell like changes in rVSMCs. , 2006, Prostaglandins & other lipid mediators.

[37]  Jeanne M Clark,et al.  The Epidemiology of Nonalcoholic Fatty Liver Disease in Adults , 2006, Journal of clinical gastroenterology.

[38]  G. Link,et al.  Fructose-Induced Fatty Liver Disease: Hepatic Effects of Blood Pressure and Plasma Triglyceride Reduction , 2005, Hypertension.

[39]  M. Bogyo,et al.  Regulation of Collagenase Activities of Human Cathepsins by Glycosaminoglycans* , 2004, Journal of Biological Chemistry.

[40]  G. Gores,et al.  Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. , 2003, The Journal of clinical investigation.

[41]  E. Brunt,et al.  Pathology of nonalcoholic steatohepatitis. , 2005, Hepatology research : the official journal of the Japan Society of Hepatology.

[42]  B. Gelb,et al.  Collagenase Activity of Cathepsin K Depends on Complex Formation with Chondroitin Sulfate* , 2002, The Journal of Biological Chemistry.

[43]  G. Gores,et al.  Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. , 2000, The Journal of clinical investigation.

[44]  W. Fiers,et al.  Cathepsin B-mediated activation of the proinflammatory caspase-11. , 1998, Biochemical and biophysical research communications.

[45]  N. Gebbia,et al.  Lysosomal cathepsins B and L and Stefin A blood levels in patients with hepatocellular carcinoma and/or liver cirrhosis: potential clinical implications. , 1997, Oncology.

[46]  N. Gebbia,et al.  Cathepsin D Serum Mass Concentrations in Patients with Hepatocellular Carcinoma and/or Liver Cirrhosis , 1996, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[47]  A. C. Webb,et al.  Human cathepsin S: chromosomal localization, gene structure, and tissue distribution. , 1994, The Journal of biological chemistry.

[48]  H. Kawasaki,et al.  Collagenolytic cathepsin B and L activity in experimental fibrotic liver and human liver. , 1992, Research communications in chemical pathology and pharmacology.